Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2007-03-20
2007-03-20
Campell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093100, C424S224100
Reexamination Certificate
active
10717101
ABSTRACT:
The subject invention relates to viruses that are able to purge (reduce or eliminate) undesirable cells in a mixture of cells. Undesirable cells can include neoplastic cells, cells mediating graft-versus host diseases, and autoimmune cells. The subject invention also relates to the purging of undesirable cells from bone marrow or peripheral blood cell harvests in the treatment of mammals including cancer patients, transplant recipients, and patients with autoimmune disease.
REFERENCES:
patent: 5677178 (1997-10-01), McCormick
patent: 6136307 (2000-10-01), Lee et al.
patent: 2001/0048919 (2001-12-01), Morris et al.
patent: 2002/0006398 (2002-01-01), Morris et al.
patent: 2004/0170607 (2004-09-01), Bell et al.
patent: 2004/0208849 (2004-10-01), Bell et al.
patent: WO 94/25627 (1994-11-01), None
patent: WO 99/18799 (1999-04-01), None
patent: WO99/18799 (1999-04-01), None
patent: WO 00/62735 (2000-10-01), None
patent: WO 01/19380 (2001-03-01), None
patent: WO01/19380 (2001-03-01), None
patent: WO 01/83710 (2001-11-01), None
patent: WO 01/83711 (2001-11-01), None
Kim et al. The Molecular Medicine Today, 1996, pp. 519-527.
Balachandran et al. J. Virol. 2001, vol. 75, No. 7, pp. 3474-3479, .
Strong et al. The EMBO J. 1998, vol. 17, No. 12, pp. 3351-3362.
Seth et al. Cancer Research 1996, vol. 56, No. 6, pp. 1346-1351.
Robert C. Mellors , Pathogenesis of HIV infection and AIDS published on 1999 at website of Cornell University Medical College: http://edcenter.med.conell.edu/CMMC—pathNotes/HIV—infection/HIV—infection—04.html.
Wolff et al. Human Gene. Ther. 1998, vol. 9, pp. 2277-2284.
PDR Electronic Library, Thomson PDR, 2002-2006 att he thomsonhc.com, p. 1-10.
Osborne et al. The oncologist 2004, vol. 9, pp. 361-377.
Weber et al. Crit. Rev. Eukaryot Gene Expr. 2000, vol. 10, No. 3-4, pp. 281-302, abstract only.
2002 Cell Genesys. Inc. website: http://www.cellgenesys.com, Mar. 31, 2005.
NIH AIDS reagent repository catalog, 2000, p. 3.
Coulon et al. J. Virol. 1989, vol. 63, No. 8, pp. 3550-3554.
Rabies Nature History published by CDC, Dec. 2003.
Stuart, “Autologous Bone Marrow Transplantation for Leukemia”, Seminars in Oncology, vol. 20, No. 5, Suppl 6, pp. 40-54, Oct. 1993.
Hammert, et al., “Purging marrow or peripheral blood stem cells for autografting”, Current Opinion in Hematology, vol. 4, pp. 423-428, 1997.
Schneidkraut, et al., “The Contribution of Animal Models to the Development of Treatments for Hematologic Revcoevery Following Myeloablative Therapy: A Review”, Journal of Hematotherapy, vol. 5, pp. 631-646, 1996.
Rummel, et al., “Future Paradigm for Autologous Bone Marrow Transplantation: Tumor Purging and Ex Vivo Production of Normal Stem and Progenitor Cells”, Journal of Hematotherapy, vol. 3, pp. 213-218, 1994.
Kvalheim, et al., “Purging of Tumor Cells from Leukapheresis Products: Experimental and Clinical Aspects”, Journal of Hematotherapy, vol. 5, pp. 427-436, 1996.
Bird, et al., “4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation in non-Hodgkin's lymphoma patients at high risk of bone marrow involvement”, Bonne Marrow Transplantation vol. 18, pp. 309-313, 1996.
Hammert, et al., “Purging autologous bone marrow with monoclonal antibodies for transplantation in acute myelogenous leukemia”, Blood Reviews, vol. 11, pp. 80-90, 1997.
Villeneuve, “Ex vivo photodynamic purging in chronic myelogenous leukaemia and other neoplasis with rhodamine derivatives”, Biotechnol. Appl. Biochem., vol. 30, pp. 1-17, 1999.
Hirai, et al., “Adenovirus p53 Purging for Human Breast Cancer Stelm Cell Products”, Acta Haematol, vol. 101, pp. 97-105, 1999.
Marini, et al. “Purging of Contaminating Breast Cancer Cells from Hematopoietic Stem Cell Grafts by Adenoviral GAL-TEK Gene Therapy and Magnetic Antibody Cell Separation”, Clinical Cancer Research, vol. 5, pp. 1557-1568, Jun. 1999.
Damon, et al., “Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment of containg mitoxantrone for acute myelogenous leukemia”, Bone Marrow Transplantation, vol. 17, pp. 93-99, 1996.
Wu, et al., “Biological Purging of Breast Cancer Cells Using an Attenuated Replication-competent Herpes Simplex Virus in Human Hematopoietic Stem Cell Transplantation”, Cancer Research, vol. 61, No. 7, pp. 3009-3015, Apr. 1, 2001.
Coffey, et al., “Reovirus Therapy of Tumors with Activated Ras Pathway”, Science, vol. 282, No. 5392, pp. 1332-1334, Nov. 13, 1998.
Stojdl, et al., “VSV Strains with Defect in their Ability to Shutdown Innate Immunity are Potent Systemic Anti-Cancer Agents”, Cancer Cell, (2003) Vol. 4, pp. 263-275.
Fernandez, et al., “Genetically Engineered Vesicular Stomatitis Virus In Gene Therapy: Application for Treatment of Malignant Disease”, Journal of Virology, (2002), vol. 76, No. 2, pp. 295-904.
Ebert, et al., “Oncolytic Vesicular Stomatitis Virus for Treatment of Orthotopic Hepatocellular Carcinoma in Immune-Competent Rats”, Cancer Research, (2003), vol. 63, pp. 3605-3611.
Ebert, et al., “Systemic Therapy of Experimental Breast Cancer Metastases by Mutant Vesicular Stomatitis Virus in Immune-Competent Mice, Cancer Gene Therapy”, (2005), vol. 12, pp. 350-358.
Porosnicu, et al., “The Oncolytic Effect of Recombinant Vesicular Stomatitis Virus is Enhanced by Expression of the Fusion Cytosine Deaminase/Uracil Phosphoribosyltransferase Suicide Gene”, Cancer Research, (2003), vol. 63, pp. 8366-8376.
Ahmed, et al., “Sensitivity of Prostate Tumors to Wild Type and M Protein Mutant Vesicular Stomatitis Viruses”, Virology, (2004), vol. 330, pp. 34-49.
Balachandran, et al., “Oncolytic Activity of Vesicular Stomatitis Virus is Effective Against Tumors Exhibiting Abberant p53, Ras, or Myc Function and Involves the Induction of Apoptosis”, Journal of Virology, (2001), vol. 75, No. 7, pp. 3474-3479.
Belch, et al., “Novel therapeutic strategies in multiple myeloma (MM): Use of shiga-like toxin (SLT) or reovirus to purge myeloma cells”, Blood, vol. 92, No. 10 suppl. 1 Part 1-2, pp. 104A-105A, Nov. 1998.
Seth, et al., “Adenovirus-mediated Gene Transfer to Human Breast Tumor Cells: An Approach for Cancer Gene Therapy and Bone Marrow Purging”, Cancer Research, vol. 56, No. 6, pp. 1346-1351, Mar. 15, 1996.
Wu, et al., “Bone Marrow Purging of Neuroblastoma by Attenuated Multimutated Herpes Simplex Virus”, Proceedings of the American Association for Cancer Research Annual, vol. 39, p. 605, Mar. 1998. (Abstract #4113).
Lichty, et al., “Identification of vesicular stomatitis virus as a leukemolytic agent”, Blood, vol. 96, No. 11 Part 2, p. 213b, Nov. 2000.
Stojdl, et al., “Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus”, Nature Medicine, vol. 6, No. 7, pp. 821-825, Jul. 2000.
Bell, et al., U.S. Appl. No. 09/664,444, “Oncolytic Virus” (filed Sep. 18, 2001).
Sinkovics, et al., J. Clin. Virol. vol. 16, pp. 1-15, 2000.
Baton, et al., Proc. Soc. Exp. iol. Med. vol. 132, pp. 20-26, 1969.
Atkins Harold L.
Bell John C.
Heilman, Jr. Conrad J.
Lichty Brian D.
Lorence Robert M.
Campell Bruce R.
Kreisler Lewis J.
Li Bao Qun
University of Ottawa
Wellstat Biologics Corporation
LandOfFree
Purging of cells using viruses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Purging of cells using viruses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Purging of cells using viruses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3794519